UG环球国际

Be the most trusted biotech company

2026-08-03

Henlius to Present Updated HLX43 TSCC Data and Seven Serplulimab Lung Cancer Studies at WCLC 2026, Addressing Unmet Needs
2026-07-31

Henlius Announces IND Approval for Its Innovative PD-L1 ADC HLX43 in Combination with Bevacizumab ± Chemotherapy
2026-07-30

Henlius' Announced First Patient Dosed for Its STEAP1×CD3×CD28 Tri-specific TCE HLX3902
2026-07-20

Henlius to Showcase 12 Research Presentations at ESMO 2026, Including U.S. Bridging Study of Serplulimab and POC of PD-L1 ADC HLX43 in Gastric Cancer
2026-07-16

First Patient Dosed in China for International Multi-centre Phase 1 Clinical Trial of Henlius’ Nivolumab Biosimilar HLX18
2026-07-13

First Patient Dosed in the U.S. for International Multi-center Phase 1 Clinical Trial of Henlius’ Subcutaneous Daratumumab Biosimilar HLX15-SC
2026-07-10

Henlius’ PD-L1×VEGF Bispecific Antibody HLX37 Receives NMPA IND Approval for a Phase 1 Study, Advancing Next-Generation IO Combination Strategy
2026-07-08

First Patient Dosed in China for Phase 1 Clinical Trial of Henlius’ Cetuximab Biosimilar HLX05-N
2026-07-06

Henlius’ Serplulimab Final Analysis in nsqNSCLC Published in Cancer Communications, Reinforcing Durable Survival Benefit